Amyris raises $34 million as it pursues skin care, sweeteners, and CBD


In California, renewable chemical company Amyris has closed most of a $34-million private placement of its common stock and warrants to purchase common stock with accredited investors, with most funds received and the remainder to be received this week. The financing was anchored by long-term investors in the company.

The financing was provided by investors such as Foris Ventures, an entity affiliated with Amyris board member John Doerr (of Kleiner Perkins Caufield & Byers), Dr. Wei-wu He, General Partner of Emerging Technology Partners, LLC, a life sciences-focused venture fund, and others.

“Our long-term investors continue to be encouraged by the performance of our products and technology. We believe they see our capabilities as being essential in disrupting large global markets by delivering the best products to meet consumer needs for natural and sustainable skin care, sweeteners and soon with highest quality and purity CBD,” says John Melo, Amyris President and CEO. “These funds support our plan to retire our May debt maturity and to continue growing our business.”